Ortin Global logo

Ortin Global PE ratio history and valuation

NSE: ORTINGLOBEBSE: 539287Pharmaceuticals & BiotechnologySmall Cap

ORTIN GLOBAL LIMITED · Formerly Ortin Laboratories · Face value ₹10 · Listed Aug 2015 on BSE, Mar 2021 on NSE
Last close ₹12.41down ₹0.34 (2.67%)

Share price at the NSE close on 28 Oct 2026. Previous close ₹12.75.

28 Oct: open ₹12.50, high ₹13.39, low ₹12.26

52-week range of traded prices to 28 Oct 2026
₹10.66Low, 28 Oct 2025₹21.30High, 9 Jun 2026
Market cap
₹10 Cr4,502nd largest listed
P/E
Lossover the last 12 months
P/B
8.16
Dividend yield
Nonein the last 12 months
ROE
−56.2%
ROCE
−52.2%
Debt to equity
0.81
Volume, NSE
2,37479.8% delivered

Ortin Global's price to book, price to sales, dividend yield and earnings yield on 28 Oct 2026, each against its own history of up to 10 years. It has no P/E: its profit over the twelve months to Jun 2026 is a loss.

Ortin Global PE ratio and valuation against its own history

  • Price to earningsLoss, last twelve months
  • Price to book8.16today

    1 year

    Median 9.64

    Today is at or above 16% of the 247 days

    3 years

    Median 5.64

    Today is at or above 71% of the 718 days

    5 years

    Median 2.13

    Today is at or above 83% of the 1,213 days

    10 years, since Nov 2018

    Median 1.75

    Today is at or above 89% of the 1,808 days

  • Price to sales139.57today

    1 year

    Median 117.40

    Today is at or above 75% of the 247 days

    3 years

    Median 27.45

    Today is at or above 92% of the 718 days

    5 years

    Median 4.36

    Today is at or above 95% of the 1,213 days

    10 years

    Median 0.64

    Today is at or above 97% of the 2,375 days

  • EV to EBITDAOperating loss, last twelve months
  • Dividend yield0.00%today

    1 year

    Median 0.00%

    Today is at or above 100% of the 247 days

    3 years

    Median 0.00%

    Today is at or above 100% of the 744 days

    5 years

    Median 0.00%

    Today is at or above 100% of the 1,239 days

    10 years

    Median 0.00%

    Today is at or above 100% of the 2,412 days

  • Earnings yield−8.95%today

    1 year

    Median −7.34%

    Today is at or above 17% of the 247 days

    3 years

    Median −9.11%

    Today is at or above 53% of the 718 days

    5 years

    Median −6.40%

    Today is at or above 33% of the 1,137 days

    10 years

    Median −1.92%

    Today is at or above 18% of the 2,099 days

Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.

How each ratio is worked out, with today's figures
  • Price to book =Market cap÷Net worth₹1.24 Cr
  • Price to sales =Market cap÷Revenue, last twelve months₹0.07 Cr
  • Enterprise value =Market cap+Borrowings₹1.01 Cr−Cash₹0.61 Cr
  • Market cap =Close×Shares in issue81,31,392at 30 Sep 2026
Net profit, last twelve months
−₹0.90 Cr
Operating profit, last twelve months
−₹1.17 Cr

Standalone accounts, the twelve months to Jun 2026, balance sheet at Mar 2026, ₹ crore.Ortin Global financials ›

Ortin Global valuation at each year end

On the last trading day of each March, the month the company's year ends.

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Market cap (₹ crore)31.130.423.812.352.518.414.314.38.011.0
Price to earnings127.9279.0Earlier quarters restated in the yearLoss11.421.4LossLossLossLoss
Price to bookNo balance sheetNo balance sheet1.00.52.01.61.31.53.58.5
Price to sales0.50.50.10.10.22.42.14.218.099.0
EV to EBITDAOperating profit not statedNo balance sheet7.49.85.529.071.5Operating lossOperating lossOperating loss
Dividend yield0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Earnings yield0.8%0.4%Earlier quarters restated in the year−4.4%8.8%4.7%−2.4%−28.5%−60.6%−8.1%
A ratio that does not exist on the day says why in its cell.

Ortin Global market cap, ten years

The last trading day of each month.

Market cap, ₹ crore

  • Market cap
₹53 Cr₹7.97 Cr₹10 CrOct 16Jan 18Apr 19Jul 20Nov 21Feb 23May 24Aug 25Oct 26

Earnings per share, book value and enterprise value

From the close on 28 Oct 2026, with the last twelve months' results.

Enterprise value
₹10 Cr
Earnings per share
−₹1.11
Book value per share
₹1.52
Dividends, last 12 months
None
Public's market cap
₹9.97 Cr

Against Pharmaceuticals

215 listed companies in Pharmaceuticals, each priced on its last trading day; Ortin Global is 209th among them by market cap. Each median leaves out Ortin Global itself and takes the other companies that have the figure.

Industry median P/E
28.1Across 157 other companies
Industry median P/B
2.9Across 190 other companies
Industry median EV/EBITDA
19.1Across 144 other companies
Industry median dividend yield
0.49%Across 89 other companies
Company
Desh Rakshak Aushdhalaya logoDesh Rakshak AushdhalayaDESHRAK1527.771.1513.00.00%
Venmax Drugs and Pharmaceuticals logoVenmax Drugs and PharmaceuticalsVENMAX15–––0.00%
Beryl Drugs logoBeryl DrugsBERLDRG1320.991.338.40.00%
Unjha Formulations logoUnjha FormulationsUNJHAFOR1225.643.1514.20.00%
Ortin Global logoOrtin GlobalORTINGLOBE10–8.16–0.00%
Dipna Pharmachem logoDipna PharmachemDPL10–––0.00%
Brawn Biotech logoBrawn BiotechBRAWN89.041.79–0.00%
Vivanza Biosciences logoVivanza BiosciencesVIVANZA613.211.3832.00.00%
Decipher Labs logoDecipher LabsDECIPHER6–0.67–0.00%
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.